Reversed-phase liquid chromatographic determination of idarubicin and its 13-hydroxy metabolite in human plasma.
A method is given for the determination of idarubicin and its main metabolite, idarubicinol, in plasma from cancer patients. Idarubicin and idarubicinol are extracted from 2-ml samples of buffered plasma (pH 8.1) using chloroform-1-heptanol (9:1). After reextraction into phosphoric acid (0.1 M), separation is performed by reversed-phase liquid chromatography on a LiChrosorb RP-2 column (5 microns) with a mobile phase of acetonitrile-water, acidified with phosphoric acid. The absolute recovery in the range 5-100 ng/ml was greater than 83% with a precision better than 8% (relative standard deviation), using photometric detection at 484 nm. Proper handling of whole blood samples containing idarubidin is essential to avoid metabolic conversion into idarubicinol. Prolonged storage of the drug and its main metabolite under alkaline conditions should be avoided to prevent chemical degradation.
Eksborg
S
S
Karolinska Pharmacy, Stockholm, Sweden.
Nilsson
B
B
D055598:Chemical Phenomena; D002621:Chemistry; D002851:Chromatography, High Pressure Liquid; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000097:blood; D006801:Humans; D006863:Hydrogen-Ion Concentration; D015255:Idarubicin / Q000097:blood*; D013050:Spectrometry, Fluorescence
C054440:idarubicinol; D015255:Idarubicin; D003630:Daunorubicin